Kieran O'Kane - Feb 23, 2021 Form 4 Insider Report for BIODESIX INC (BDSX)

Role
Chief Commercial Officer
Signature
/s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane
Stock symbol
BDSX
Transactions as of
Feb 23, 2021
Transactions value $
$0
Form type
4
Date filed
3/14/2022, 05:51 PM
Next filing
Feb 10, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Stock Options (Right to buy) Award $0 +4.21K $0.00 4.21K Feb 23, 2021 Common Stock 4.21K $0.77 Direct F1, F2
transaction BDSX Stock Options (Right to buy) Award $0 +4.21K +99.98% $0.00 8.42K Mar 10, 2022 Common Stock 4.21K $0.77 Direct F1, F3
transaction BDSX Stock Options (Right to buy) Award $0 +6.16K $0.00 6.16K Mar 10, 2022 Common Stock 6.16K $2.29 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 15, 2020, the Reporting Person was granted an option to purchase 8,423 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2020 and 2021 fiscal years.
F2 On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 4,212 shares underlying the option.
F3 On March 10, 2022, the Compensation Committee confirmed the performance criteria were met for fiscal year 2021, resulting in the vesting of 4,211 shares underlying the option.